Please upgrade your browser.
After 96 hours of exposure to a 20-to-1 rice callus solution, 95 percent of the kidney cancer cells were killed...
AGS-003, first fully personalized, dendritic-based immunotherapy being evaluated in combination with targeted therapy for mRCC.
Aveo Pharmaceuticals Inc. said Thursday it plans to sell about $50 million in stock.
A redshirt junior guard, Shrive has raised nearly $70,000 for the Kidney Cancer Association during his Penn State career.
The report also includes information on Renal Cell Carcinoma market.
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC.
Many physicians have expressed concerns about how comparative effectiveness analysis will be used by payors and insurers.
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate.
A deadline for eliminating disparities by 2010 has come and gone.
India is taking another swipe at Big Pharma.
|Powered by NeonCRM|